Is warfarin obsolete in the era of new anticoagulants?MAHAFFEY, Kenneth W.Dialogues in cardiovascular medicine. 2012, Vol 17, Num 3, pp 206-213, issn 1272-9949, 8 p.Article

Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes : The SYNERGY trialMAHAFFEY, Kenneth W; FERGUSON, James J.The American heart journal. 2005, Vol 149, Num 4, pp S81-S90, issn 0002-8703, SUPConference Paper

Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: A review and guide to patient selectionATWATER, Brett D; ROE, Matthew T; MAHAFFEY, Kenneth W et al.Drugs (Basel). 2005, Vol 65, Num 3, pp 313-324, issn 0012-6667, 12 p.Article

A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromesCALIFF, Robert M; PETERSEN, John L; HASSELBLAD, Vic et al.The American heart journal. 2005, Vol 149, Num 4, pp S91-S99, issn 0002-8703, SUPConference Paper

Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: Integrating pharmacologic and mechanical reperfusion strategiesWATERS, Richard E; MAHAFFEY, Kenneth W; GRANGER, Christopher B et al.The American heart journal. 2003, Vol 146, Num 6, pp 958-968, issn 0002-8703, 11 p.Article

Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) TrialMAHAFFEY, Kenneth W; HELD, Claes; KHURMI, Nardev S et al.Journal of the American College of Cardiology. 2014, Vol 63, Num 15, pp 1493-1499, issn 0735-1097, 7 p.Article

Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non―ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker TrendsTRICOCI, Pierluigi; LEONARDI, Sergio; HARRINGTON, Robert A et al.Journal of the American College of Cardiology. 2013, Vol 62, Num 3, pp 242-251, issn 0735-1097, 10 p.Article

The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE TrialPARFREY, Patrick S; CHERTOW, Glenn M; WHEELER, David C et al.The Journal of clinical endocrinology and metabolism. 2013, Vol 98, Num 12, pp 4834-4844, issn 0021-972X, 11 p.Article

Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialCHERTOW, Glenn M; CORREA-ROTTER, Ricardo; MIX, Thomas-Christian et al.Nephrology, dialysis, transplantation (Print). 2012, Vol 27, Num 7, pp 2872-2879, issn 0931-0509, 8 p.Article

Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction TrialHUDSON, Michael P; ARMSTRONG, Paul W; GRANGER, Christopher B et al.Circulation. Cardiovascular quality and outcomes (Print). 2011, Vol 4, Num 2, pp 183-192, issn 1941-7713, 10 p.Article

Bleeding complications with the P₂Y₁₂ receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trialBECKER, Richard C; PIERRE BASSAND, Jean; LOPEZ-SENDON, Jose et al.European heart journal. 2011, Vol 32, Num 23, pp 2933-2944, issn 0195-668X, 12 p.Article

Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromesYAN, Raymond T; YAN, Andrew T; GOODMAN, Shaun G et al.European heart journal. 2010, Vol 31, Num 8, pp 958-966, issn 0195-668X, 9 p.Article

Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease : A Randomized TrialSTONE, Gregg W; MIDEI, Mark; SOOD, Poornima et al.JAMA, the journal of the American Medical Association. 2008, Vol 299, Num 16, pp 1903-1913, issn 0098-7484, 11 p.Article

Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndromeLEUNG, Steve; GALLUP, Dianne; CALIFF, Robert M et al.The American heart journal. 2008, Vol 156, Num 1, pp 177-184, issn 0002-8703, 8 p.Article

Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes : Results from 4 large clinical trialsGALLA, John M; MAHAFFEY, Kenneth W; SIMOONS, Maarten L et al.The American heart journal. 2005, Vol 151, Num 1, pp 16-24, issn 0002-8703, 9 p.Article

Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-I trial)KANDZARI, David E; GRANGER, Christopher B; LEE, Kerry L et al.The American journal of cardiology. 2004, Vol 93, Num 4, pp 458-461, issn 0002-9149, 4 p.Article

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trialGRANGER, Christopher B; MAHAFFEY, Kenneth W; ARMSTRONG, Paul W et al.Circulation (New York, N.Y.). 2003, Vol 108, Num 10, pp 1184-1190, issn 0009-7322, 7 p.Article

Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)HALPERIN, Jonathan L; HANKEY, Graeme J; PAOLINI, John F et al.Circulation (New York, N.Y.). 2014, Vol 130, Num 2, pp 138-146, issn 0009-7322, 9 p.Article

Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF TrialKA SING LAWRENCE WONG; DAI YI HU; FOX, Keith A. A et al.Stroke (1970). 2014, Vol 45, Num 6, pp 1739-1747, issn 0039-2499, 9 p.Article

Determinants of plasma vitamin D levels in patients with acute coronary syndromesRODRIGUEZ, Gabriella; STARR, Aijing Z; KLEIMAN, Neal S et al.European journal of clinical investigation. 2011, Vol 41, Num 12, pp 1299-1309, issn 0014-2972, 11 p.Article

Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI)FRENCH, John K; HELLKAMP, Anne S; ARMSTRONG, Paul W et al.The American journal of cardiology. 2010, Vol 105, Num 1, pp 59-63, issn 0002-9149, 5 p.Article

Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGYSPINLER, Sarah A; MAHAFFEY, Kenneth W; WHITEY, Harvey D et al.International journal of cardiology. 2010, Vol 144, Num 1, pp 36-41, issn 0167-5273, 6 p.Article

ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) TrialBULLER, Christopher E; YULING FU; GRANGER, Christopher B et al.Circulation (New York, N.Y.). 2008, Vol 118, Num 13, pp 1335-1346, issn 0009-7322, 12 p.Article

Publication or presentation of results from multicenter clinical trials : Evidence from an academic medical centerTURER, Aslan T; MAHAFFEY, Kenneth W; COMPTON, Kate L et al.The American heart journal. 2007, Vol 153, Num 4, pp 674-680, issn 0002-8703, 7 p.Article

Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction : results from the CARDINAL studyVOGELZANG, Mathijs; ZIJISTRA, Felix; TODARO, Thomas G et al.European heart journal. 2006, Vol 27, Num 11, issn 0195-668X, 1264-1265,1289-1297 [11 p.]Article